Returns
Every filed return on the register. Filter, then open any return on lobbying.ie to read it in full.
Showing returns filed by Eli Lilly and Company .
Filed returns
15
match these filters
| Period | Registrant | Policy area | Subject, as filed | Officials named | Link |
|---|---|---|---|---|---|
| Sep–Dec 2024 | Eli Lilly and Company | Economic Development and Industry | Update on company operations in Ireland and EU (Public policy or programme) | 23 | On lobbying.ie |
| May–Aug 2024 | Eli Lilly and Company | Economic Development and Industry | Investment and Economic Impact of Lilly Kinsale. (Public policy or programme) | 15 | On lobbying.ie |
| May–Aug 2024 | Eli Lilly and Company | EU Affairs | EU Pharmaceutical Legislation (Legislation) | 11 | On lobbying.ie |
| Jan–Apr 2024 | Eli Lilly and Company | EU Affairs | EU Pharmaceutical Legislation (Legislation) | 2 | On lobbying.ie |
| Sep–Dec 2023 | Eli Lilly and Company | EU Affairs | EU Pharmaceutical Legislation (Legislation) | 6 | On lobbying.ie |
| May–Aug 2023 | Eli Lilly and Company | EU Affairs | Introduction to Lilly Corporate, and company operations in Ireland (Public policy or programme) | 3 | On lobbying.ie |
| Jan–Apr 2023 | Eli Lilly and Company | Economic Development and Industry | Invitation to American Chamber Event (Public policy or programme) | 4 | On lobbying.ie |
| Jan–Apr 2023 | Eli Lilly and Company | Economic Development and Industry | New Lilly manufacturing site in Limerick. (Public policy or programme) | 58 | On lobbying.ie |
| Sep–Dec 2022 | Eli Lilly and Company | EU Affairs | EU Chemicals Strategy (Legislation) | 1 | On lobbying.ie |
| May–Aug 2022 | Eli Lilly and Company | EU Affairs | Updated EU Industrial Strategy (Public policy or programme) | 1 | On lobbying.ie |
| May–Aug 2021 | Eli Lilly and Company | Economic Development and Industry | EU Pharmaceutical Strategy (Public policy or programme) | 1 | On lobbying.ie |
| Jan–Apr 2021 | Eli Lilly and Company | Economic Development and Industry | EU Pharmaceutical Strategy (Public policy or programme) | 4 | On lobbying.ie |
| May–Aug 2017 | Eli Lilly and Company | Economic Development and Industry | General update on Lilly's business in Ireland and Europe, the opportunities and challenges facing the company and the pharma sector in the next 5 years - incl challenges of BREXIT; the impact of European policy (across… (Public policy or programme) | 1 | On lobbying.ie |
| Jan–Apr 2017 | Eli Lilly and Company | EU Affairs | EU Regulation REACh - Registration, Evaluation, Authorisation and Restriction of Chemicals (Legislation) | 2 | On lobbying.ie |
| Jan–Apr 2017 | Eli Lilly and Company | EU Affairs | EU Regulation REACh - Registration, Evaluation, Authorisation and Restriction of Chemicals (Legislation) | 3 | On lobbying.ie |
Policy areas in these returns
| Public policy area | Filed returns | Share | Relative to the largest |
|---|---|---|---|
| EU Affairs | 8 | 53.3% | |
| Economic Development and Industry | 7 | 46.7% |